SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will present at the
39th Annual J.P. Morgan Healthcare Conference at
2:00 p.m. Eastern Time on Monday Jan.
11, 2021. Kevin Gorman, Chief
Executive Officer, will present at the conference.
The live presentation will be webcast and may be accessed on the
Company's website under Investors at www.neurocrine.com. A replay
of the presentation will be available on the website approximately
one hour after the conclusion of the events and will be archived
for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a neuroscience-focused, biopharmaceutical company dedicated to
discovering, developing and delivering life-changing treatments for
people with serious, challenging and under-addressed neurological,
endocrine and psychiatric disorders. The company's diverse
portfolio includes FDA-approved treatments for tardive dyskinesia,
Parkinson's disease, endometriosis*, uterine fibroids* and clinical
programs in multiple therapeutic areas. For nearly three decades,
Neurocrine Biosciences has specialized in targeting and
interrupting disease-causing mechanisms involving the
interconnected pathways of the nervous and endocrine systems. For
more information, visit neurocrine.com, and follow the
company on LinkedIn. (*in collaboration with
AbbVie)
###
View original content to download
multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301200496.html
SOURCE Neurocrine Biosciences, Inc.